


Weekly discussion of biotech news w/ @daphnezohar @bradloncar @timopler @LifeSciVC, @cngarabedian, top analysts & other biotech insiders


One takeaway from lots of convos in NYC is that everyone is VERY confident that Anthropic is going to have a successful IPO pricing tonight.

It's Over-ton. (From @maxonwifi ) endpoints.news/white-house-p…

You mean you don't appreciate when your biotech holding with fantastic data is up 40% in the premarket with 50% more upside to fair value, and then gets crushed to flat at open because risk at a large MM market sold a pod's holdings for blowing up on a MRNA short position, and then a quant momentum strategy shorts it because of the big pullback, and then a quant fund piles on the selling pressure by hedging their AI long trade by shorting interest rate risk out with a SMID cap biotech short, and then the stock is down 15% and no one knows why so an analyst publishes that obviously the stock is down because (pick random datapoint that doesn't matter) but in reality was just persuaded on a call with a pod PM to be bearish because they had a short position they needed to press and then that narrative gets entrenched and you're sitting here wondering why this company swung 60% down on great data and is financed through CF+ and trades at a big discount to some other biotech company and the world moves on to the next company with data tomorrow and no one cares to re-visit your company because it's a "catalyst desert" for 3 months? And pharma then passes over it and buys an undifferentiated pre-clinical private China asset instead of your company, which blows up on them a year later and they write it down but now your company needs to finance at a discount to the prior data? How could you not love that?
I miss the days when the price discovery was driven by good ol' fashion fundamental analysis. All quant algos and retail now fucking everything up.

Wow - Total destruction in biotech. If you're near neutral L/S and benchmarking to $XBI, it's possible this is about the worst it has ever been. Bizarre year no doubt. Hard to imagine sentiment getting much worse...but still, we'd better all be crossing our fingers and toes for some M&A up to/at JPM. Absolute misery for now, but we've seen time and time again...when biotech finally turns the corner, the bounce back up is steep. 🤞🤞🤞 Good luck, folks!

Maybe stating the obvious, but I think a preclinical biotech raising $5B is a colossal waste of money. Let’s assume their platform is fantastic and will generate a ton of great clinical candidates. You still can’t scale biotech work just by throwing cash at it. If they try to take forward 50 programs in parallel they will make mistakes and get sloppy. This is different than scaling up in AI, where the main constraint and expense is building more computational capacity—a much more readily scalable activity.
Isomorphic Labs, the AI drug-discovery platform that was spun out of Google’s DeepMind in 2021, has raised $5 Billion in a Series C funding round. spr.ly/6010ByTYZ2

APPROACH Phase 3 Topline Study Results $HELP Link: ir.helus.com/static-files/1c…

$SLS The company on the call said that they ran the "pre specified" analysis, but they pre-specified ITT, mITT, and Per Protocol analysis and do not identify which one these data are. No commentary on secondaries hitting either. FDA will look at ITT for approval. Why no Q&A? This essentially gives $SLS the ability to produce whatever p-value they want on a "pre specified" basis but in reality, only ITT matters.

$SLS +300% (Market cap: ~$6B) Sellas Life Sciences' experimental cancer vaccine extended survival in a pivotal Phase 3 leukemia trial, meeting its primary endpoint. Its vaccine, galinpepimut-S (GPS), reduced the risk of death by 41% compared with the best available treatment in patients with acute myeloid leukemia (AML), with a statistically significant hazard ratio of 0.59 (p=0.035). Median overall survival: • GPS vaccine: 24.0 months • Best available treatment: 14.7 months That's a 9.3-month improvement in median survival. The 126-patient REGAL trial focused on AML patients in their second or later remission who were unable to undergo a stem cell transplant, a group with limited treatment options. Licensed from Memorial Sloan Kettering, GPS is designed to stimulate the immune system to target residual leukemia cells expressing the WT1 protein. The vaccine was generally well tolerated, with mostly mild to moderate side effects, primarily injection-site reactions. No new safety concerns were identified. Sellas now plans to meet with the FDA to discuss an accelerated filing strategy, targeting a submission for approval in the first half of 2027. Full secondary endpoint results are still pending, and the vaccine remains investigational.

$SLS REGAL hit. HR 0.59, median OS 24.0 vs 14.7 months, p=0.035 two-sided, at the prespecified 80 deaths I wrote you'd need roughly 0.645 or better at 80 events. 0.59 clears it. and it's prespecified OS, the exact thing FDA told Summit it needed what I like most: the BAT arm lived 14.7 months. not a weak control. GPS added ~9 months on top of that what I'd still watch: - no CI in the release. HR 0.59 at 80 events would normally give p≈0.02. back-solving from 0.035, the CI is probably around 0.36-0.96. a real win, not a blowout - open-label, 126 patients, single trial. "accelerated filing strategy" isn't accelerated approval. BLA targeted 1H27 - landmark OS and secondaries still to come at a congress $7.47 last close, ~$1.5B market cap. my model had it at roughly 25% odds

Both Hengrui and Isomorphic now have ~$50B valuations. One is China's largest innovative biopharma player, one is bio AI's largest... Which one will have more impact on human disease over the next 10 years? Which one will drive the biggest R&D Productivity improvements? Hengrui has 34 branded approved drugs, 100+ drugs in its clinical pipeline and 400+ ongoing clinical trials - and $4B in revenues. Isomorphic has its Drug Design Engine, that goes way beyond AlphaFold as a first-principles AI drug R&D architecture, and It has yet to put it's lead program into clinical testing, but is expected to in 2027 with many more after that... Both have lots of global partners. Both have tons of cash to invest. Both have enormous ambitions. Which one will deliver the most for patients and the ecosystem by 2036? China vs AI. Predator vs Alien. Godzilla vs Kong. The great "battle" of our time...

Thrilled to announce $5B in funding for @IsomorphicLabs to accelerate our mission to Solve All Disease. We continue to make rapid progress reimagining drug design from first principles with AI to radically cut the time & cost to find new medicines. Gradually, then all at once...

*Up to $5.9B (no upfront disclosed).
Eli Lilly continues to be pharma’s biggest shopaholic. more on Stipple Bio's up to $5.9 billion partnership w/Lilly from @leilei_wuu Lilly has done dozens of M&A, licensing and collabs in past two years to continue dominating pharma for the long-term endpoints.news/lilly-strikes…


#BiotechHangout & @BiotechTV are heading back to San Francisco for #JPM27! Join us for a night of in-person mingling with Biotech Hangout hosts & friends at Persona (same location as previous years) on Tuesday, January 12, 2027, from 7-10pm PT. A special thanks to our returning co-sponsors CFGO and @FTIConsulting, who signed on early to support the event again this year. Interested in sponsoring the event? Send us an email at team@biotechhangout.com. Space is limited, so reach out soon. RSVP to the event here: forms.gle/tSb6dFHYzP8SvgKs7 All are welcome & we hope to see you there! #JPMHangout

I have a controversial take on today's Ivo CRL First, I think THIS CRL is warranted. $SMMT played a trick by pooling two cohorts with drastically different FU and asked regulator to approve altogether while the western cohort is yet matured (and China cohort is super-matured).